Lifestance Health Group, Inc. SEC Filings

Silversmith Partners reported an insider sale of common stock in LifeStance Health Group, Inc. (LFST). On 08/18/2025 the Silversmith Entities disposed of 3,592,357 shares at a price of $5.07 per share. After that transaction the reporting parties beneficially owned 14,324,197 shares on an indirect basis. The filing breaks down the indirect holdings: Silversmith Capital Partners I-A, L.P. holds 9,855,844 shares, Silversmith Capital Partners I-B, L.P. holds 3,565,133 shares, and Silversmith Capital Partners I-C, L.P. holds 903,220 shares. The report includes standard disclaimers that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest and notes a stockholders agreement that may create a Section 13(d) "group" with other large holders. The form is signed by Jeffrey R. Crisan on 08/20/2025.

Darren M. Black, a director and 10% owner affiliate, reported a sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) on 08/18/2025 at a price of $5.07 per share. The shares sold were held across multiple Summit-related funds as detailed in the filing. After the transaction, the reporting parties continue to beneficially own a total of 33,524,715 shares held indirectly through Summit entities. The filing clarifies the ownership chain: Mr. Black is a Managing Director and Member of Summit Master Company, LLC, which through a series of partnerships and management relationships holds voting and dispositive authority over the reported shares.

Insider sale by Summit Partners entities: On 08/18/2025 multiple Summit-related entities reported an aggregate sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) at a price of $5.07 per share. After the reported transactions, the entities collectively beneficially own 33,524,715 shares held across five Summit funds and entities. The filings identify Summit Partners, L.P. as the manager with voting and dispositive authority exercised by a four-person investment committee. The report was signed and filed on 08/20/2025 by authorized representatives of the Summit entities.

LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 894,098 shares of Common Stock through Morgan Stanley & Co. LLC, with an aggregate market value of $4,837,070.18. The filing lists the approximate date of sale as 08/18/2025 and the securities exchange as NASDAQ.

The shares were acquired pre-IPO on 06/10/2021 from the issuer, with 5,130,460 shares originally acquired on that date. The filer reports no securities sold in the past three months and includes the required certification that no undisclosed material adverse information is known.

LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 2,471,741 shares of common stock through Morgan Stanley & Co. LLC with an aggregate market value of $13,372,118.81. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025 on NASDAQ. The securities to be sold were originally acquired on 06/10/2021 in pre-IPO transactions, with 14,183,201 shares reported as acquired at that time. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025. The filing states an aggregate market value of $1,225,462.38 and reports 388,936,394 shares outstanding. The securities were acquired in a pre-IPO transaction on 06/10/2021, when 1,299,792 shares were obtained from the issuer; payment is noted as equity interests purchased pre-IPO. No sales by the reporting person in the past three months are disclosed. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

LifeStance Health Group, Inc. (LFST) filed a Form 144 disclosing a proposed sale of 3,214,648 shares of Common Stock through Morgan Stanley & Co. LLC on 08/18/2025 on NASDAQ, with an aggregate market value of $17,391,245.68. The shares were originally acquired 06/10/2021 in a pre-IPO transaction from LifeStance Health Group Inc.; the filing reports total outstanding shares of 388,936,394. The filer certifies there is no undisclosed material adverse information and notes no securities were sold by the filer in the past three months.

LifeStance Health Group, Inc. (LFST) submitted a Form 144 notice for a proposed sale of securities under Rule 144. The filing shows 5,148,494 shares of Common Stock are planned to be sold through Morgan Stanley & Co. LLC on or about 08/18/2025, with an aggregate market value of $27,853,352.54 and 388,936,394 shares outstanding. The securities were acquired on 06/10/2021 in a pre-IPO transaction, totaling 29,542,786 shares acquired on that date. No securities were reported sold in the past three months. The filer certifies they do not possess undisclosed material adverse information about the issuer.